Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) Stock Information | RedChip

Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) Listen to this Section


$4.67
-0.2300 ( -4.69% ) 91.8K

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Market Data


Open


$4.67

Previous close


$4.90

Volume


91.8K

Market cap


$287.23M

Day range


$4.60 - $4.90

52 week range


$2.44 - $8.84

Insider Ownership Transactions

Total Amount Purchased: -215,417.00 | $ -1,005,997.39

Date Type Amount Purchased Purchaser
2024-07-09 Sale -1610.00 Dunn Edmund
2024-06-13 Sale -22100.00 Behbahani Ali
2024-06-13 Sale -22100.00 Siu Christine
2024-06-13 Sale -22100.00 SCHIFF ANDREW N
2024-06-13 Sale -22100.00 Skvarka Jan
2024-06-13 Sale -22100.00 Manning Anthony M.
2024-06-13 Sale -22100.00 Blackwell Kimberly
2024-06-05 Sale -1207.00 Dunn Edmund
2024-06-05 Sale -40000.00 Nickson Philip
2024-06-05 Sale -40000.00 Townson Sharon

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 13 Aug 08, 2024
10-q Quarterly Reports 75 Aug 08, 2024
4 Insider transactions 1 Jul 09, 2024
8-k 8K-related 13 Jun 27, 2024
4 Insider transactions 1 Jun 13, 2024
4 Insider transactions 1 Jun 13, 2024
4 Insider transactions 1 Jun 13, 2024
4 Insider transactions 2 Jun 13, 2024
4 Insider transactions 1 Jun 13, 2024
4 Insider transactions 1 Jun 13, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.